Session Information
Date: Monday, June 20, 2016
Session Title: Parkinsonism, MSA, PSP (secondary and parkinsonism-plus)
Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To collect comprehensive and standardized clinical data and to create a repository of biological samples and cell lines from probable and possible MSA patients and age and sex matched controls.
Background: Multiple system atrophy (MSA) is a rare neurodegenerative disease of unknown etiology. For rare diseases, the development of multicenter registries may help in collecting data and define its natural progression. The Catalan Multiple System Atrophy-Registry (CMSAR) is an academic network of established movement disorders experts from tertiary centers across Catalonia with the University Hospital Clinic as coordinating center, which was constituted in March 2015.
Methods: Both MSA and healthy subjects will undergo a comprehensive longitudinal clinical assessments and biosampling every 6 months for a total period of three years. We are collecting demographic, epidemiological and clinical data covering motor and non-motor symptoms (including depressive symptoms, apathy, and other neuropsychiatric and cognitive features). Biosample set includes blood (serum, plasma, whole blood and RNA), CSF, urine and fibroblasts from skin biopsy. The study received approval from the respective review boards of all the participating institutions and all subjects have provided and are providing their written informed consent ahead of any procedure. The CMSAR project is supported by a grant from "Fundació La Marató de TV3".
Results: Until now we have included 16 consecutive MSA patients. Nine patients reached the diagnosis of MSA cerebellar type and in the 38% of the whole group the diagnosis was probable. The mean age was 62 years (±7), with mean age of onset of disease of 57 (±7). The main symptom of onset was ataxia and 81% presented RBD. None of patients had depression or dementia at the time of the first cross-sectional evaluation. Recruitment is ongoing and longitudinal data are not available yet.
Conclusions: With this project potential biomarkers and prospective data concerning disease progression will be available. Such data might allow planning more effective trials within the next years.
To cite this abstract in AMA style:
F. Antonelli, E. Muñoz, J. Pagonabarraga, J. Hernández-Vara, A. Bayes, O. de Fabregues, F. Valldeoriola, E. Tolosa, Y. Compta, M. Ezquerra, R. Fernandez, M. Calopa, S. Jauma, M. Pujol, V. Puente, A. Cámara, L. Planellas, M.J. Martí. The Catalan multiple system atrophy-registry (CMSAR) [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/the-catalan-multiple-system-atrophy-registry-cmsar/. Accessed June 14, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-catalan-multiple-system-atrophy-registry-cmsar/